Abstract:We showed previously that dietary supplementation with oil from the marine zooplankton Calanus finmarchicus (Calanus oil) attenuates obesity, inflammation, and glucose intolerance in mice. More than 80% of Calanus oil consists of wax esters, i.e., long-chain fatty alcohols linked to long-chain fatty acids. In the present study, we compared the metabolic effects of Calanus oil-derived wax esters (WE) with those of purified eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) ethyl esters (E/D) in a mouse mo… Show more
“…Table 2 reports new drugs and drug derivatives obtained by different marine organisms proposed in anti-obesity treatment [62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94]. …”
Metabolic disorder has been frequently observed in chronic obstructive pulmonary disease (COPD) patients. However, the exact correlation between obesity, which is a complex metabolic disorder, and COPD remains controversial. The current study summarizes a variety of drugs from marine sources that have anti-obesity effects and proposed potential mechanisms by which lung function can be modulated with the anti-obesity activity. Considering the similar mechanism, such as inflammation, shared between obesity and COPD, the study suggests that marine derivatives that act on the adipose tissues to reduce inflammation may provide beneficial therapeutic effects in COPD subjects with high body mass index (BMI).
“…Table 2 reports new drugs and drug derivatives obtained by different marine organisms proposed in anti-obesity treatment [62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94]. …”
Metabolic disorder has been frequently observed in chronic obstructive pulmonary disease (COPD) patients. However, the exact correlation between obesity, which is a complex metabolic disorder, and COPD remains controversial. The current study summarizes a variety of drugs from marine sources that have anti-obesity effects and proposed potential mechanisms by which lung function can be modulated with the anti-obesity activity. Considering the similar mechanism, such as inflammation, shared between obesity and COPD, the study suggests that marine derivatives that act on the adipose tissues to reduce inflammation may provide beneficial therapeutic effects in COPD subjects with high body mass index (BMI).
“…Calanus finmarchicus is the most abundant herbivorous zooplankton that that are enriched in both n-3 PUFA and LCMUFA [38]. Several studies showed beneficial effect of dietary Calanus oil in CVD risk, such as reducing atherosclerotic plaque formation, abdominal fat accumulation and hepatic steatosis, and improving glucose tolerance in mice through multiple mechanisms, including regulation of inflammatory response-associated gene expression in livers and adipose tissues [39–41]. Nevertheless, because these marine oils also contain considerable amounts of n-3 PUFA and intake of these marine oils increased plasma and organ levels of EPA and DHA, one cannot exclude the possibility that the benefit from this diet was only due to n-3 PUFA consumption.…”
Regular fish/fish oil consumption is widely recommended for protection against cardiovascular diseases (CVD). Fish and other marine life are rich sources of the cardioprotective long-chain n-3 polyunsaturated fatty acids (n-3 PUFA) eicosapentaenoic acid (C20:5 n-3; EPA) and docosahexaenoic acid (C22:6 n-3; DHA). The lipid content and fatty acid profile of fish, however, vary greatly among different fish species. In addition to n-3 PUFA, certain fish, such as saury, pollock, and herring, also contain high levels of long-chain monounsaturated fatty acids (LCMUFA), with aliphatic tails longer than 18 C atoms (i.e., C20:1 and C22:1 isomers). Compared with well-studied n-3 PUFA, limited information, however, is available on the health benefits of marine-derived LCMUFA, particularly in regard to CVD. Our objective in this review is to summarize the current knowledge and provide perspective on the potential therapeutic value of dietary LCMUFA-rich marine oil for improving CVD risk factors. We will also review the possible mechanisms of LCMUFA action on target tissues. Finally, we describe the epidemiologic data and small-scaled clinical studies that have been done on marine oils enriched in LCMUFA. Although there are still many unanswered questions about LCMUFA, this appears to be promising new area of research that may lead to new insights into the health benefits of a different component of fish oils besides n-3 PUFA.
“…Analysis of Calanus Oil have shown that levels of heavy metals and organic pollutants are well below the limits specified for marine oils by the Commission Regulation (EC) No1881/2006 and 629/2008 (Commission of the European Communities) (manuscript in preparation). Recent studies suggest that inclusion of low levels of Calanus oil or isolated wax esters in feed to rodents on a Western type high fat diet (HFD), may reduce atherogenesis and have other positive health effects such as reduced abdominal obesity, reduced adipose tissue inflammation and improvement in systemic glucose tolerance .…”
Oil extracted from the marine copepod Calanus finmarchicus contains the long chain omega-3 fatty acids eicosapentaenoic acid and DHA in addition to stearidonic acid (18:4n-3). Unlike other marine lipids, the fatty acids in this oil are esterified with long chain fatty alcohols as wax esters. The aim of this study was to examine the fate of the wax esters in oil from C. finmarchicus when given as a 2% supplement in a high fat diet to C57BL/6J mice for 11 weeks. The study confirmed that feeding mice a high fat diet supplemented with a small amount of oil containing wax esters reduced the body weight gain. During digestion, wax esters were hydrolyzed and the fatty acids absorbed since the fatty acid composition of the adipose tissue and liver reflected the enrichment with the Calanus oil. The composition of the liver lipids demonstrated elongation and desaturation of the C18 omega-3 fatty acids from the feed and accumulation of longer chained omega-3 fatty acids. Elevated levels of FFA and FAOH in the feces suggest that the absorption process, not the hydrolysis, could be a rate limiting step in utilization of small amounts of wax esters included in high fat diets in mice.Practical applications: The limited amount of available fish oil has led to extensive search for alternative sources of long-chain PUFA. One suggestion is to harvest at lower trophic levels, like small crustaceans, which may be abundantly present in the oceans. In this investigation, we have studied the effects of including the astaxanthin-rich oil from the marine copepod C. finmarchicus in a high fat diet in mice. This oil is different from other marine oils since most of the fatty acids are esterified to long-chain fatty alcohols, not in TAG, and that stearidonic acid is the major omega-3 fatty acid present. The results provide knowledge and understanding of aspects related to digestion and possible physiological effects of including small amounts of marine wax esters in diets.Abbreviations: ALA, alpha linolenic acid; þCal, inclusion of 2% calanus oil; DPA, docosapentaenoic acid; EE, ethyl ester; EPA, eicosapentaenoic acid; eWat, epididymal white adipose tissue; FAOH, fatty alcohol; FFA, free fatty acid; HFD, high fat diet; HPLC-ELSD, HPLC coupled with an evaporative light scattering detector; LC-PUFA, long-chain PUFA; pWat, perirenal white adipose tissue; SDA, stearidonic acid; WE, wax ester 1718Eur.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.